Celgene Corp. (CELG)

Index: Nasdaq 100
1.31%
$1.35
$104.50
23:26 21/11/17
$104.50
23:26 21/11/17
DAILY VARIATION
1.31%
$1.35
VOLUME
7,068,730
DATA
52 Week High
$146.52
52 Week Low
$98.17
Shares Issued
787.32m
Market Cap
$82,274.62m
RiskGrade
245
Beta
0.45
MENU

Celgene Corp. Overview

Celgene engages in the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory-related diseases in the United States. It operates in two segments: Human Pharmaceuticals and Stem Cell Therapies.

Intraday Chart

Historic Charts

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn 28.3% 55.1%
ROCE 42.1%
Latest F'cast
P/E 40.7 1,420.2
PEG 1.5 0.1
Pr/Revenue 7.4 6.3
Pr/Book 12.5
Latest F'cast
Revenue 22.1% -1.7%
PBT 17.2% n/a
EPS 27.2% 3.4%
DPS n/a 0.0%

Key Fundamentals

slide to see more
Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
2012-12-31 5,506.70 1,681.50 169.00¢ 23.2 1.4 17% n/a 0.0%
2013-12-31 6,362.30 1,665.40 175.00¢ 48.3 13.6 4% n/a 0.0%
2014-12-31 7,563.80 2,327.40 249.00¢ 44.9 1.1 42% n/a 0.0%
2015-12-31 9,161.10 2,023.50 202.00¢ 59.3 -3.1 -19% n/a 0.0%
2016-12-31 11,184.60 2,372.50 257.00¢ 45.0 1.7 27% n/a 0.0%

Forecast

slide to see more
Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
2017-12-31 12,974.20 7,147.17 733.07c 1,420.2 7.7 185% 0.00c 0.0%
2018-12-31 14,825.88 8,346.50 873.93c 1,191.8 62.0 19% 0.00c 0.0%

Regulatory News

No results found

Newspaper Links

No results found